Skip to content
ATLAS PREP HQ
Cognitive

Pinealon

Glu-Asp-Arg (EDR) tripeptide bioregulator

Short peptide bioregulator research focused on neuroprotection, cognition, and age-related brain function.

Preclinical Evidence

Route

Subcutaneous in the community educational protocol

Common format

10 mg vial

Research focus

cognition

Evidence level

Preclinical Evidence

Typical cycle

10–20 days

Cognitive research motifCognitive

Pinealon in 30 seconds

Atlas Fast Read

What it is

Glu-Asp-Arg (EDR) tripeptide bioregulator

Why people care

Short peptide bioregulator research focused on neuroprotection, cognition, and age-related brain function.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

Pinealon is scientifically interesting for cognition, neuroprotection, but the current case is driven mainly by cell and animal data.

Overview

What is Pinealon?

Pinealon is glu-Asp-Arg (EDR) tripeptide bioregulator. Short peptide bioregulator research focused on neuroprotection, cognition, and age-related brain function.

Pinealon is another short peptide from the Khavinson bioregulator program. Russian and Eastern European research has explored neuroprotection, cognition, and age-related cellular changes.

Mechanism

How it works

Proposed to influence gene expression and cellular stress responses in neural tissue. Preclinical studies report lower reactive oxygen species, altered apoptosis/cell-cycle signaling, and improved neuronal survival.

Research areas

cognitionneuroprotectionoxidative stresscircadian/aging research

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Human evidence is limited to small peptide-bioregulator studies and regional reports, without large independent trials establishing cognitive or anti-aging efficacy. Most mechanistic confidence comes from preclinical work.

Preclinical evidence

Cell and animal work reports antioxidant, anti-apoptotic, neuroprotective, and gene-regulatory effects. Human clinical confirmation is limited.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community reference: 1–2 mg/day with titration over a short course.

Frequency

Once daily.

Timing

Morning or early afternoon in the community reference.

Route

Subcutaneous in the community educational protocol; other literature includes oral/injectable forms.

Cycle length

10–20 days

Reconstitution

Community reference: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C; avoid repeated freeze-thaw.

Monitoring

No validated monitoring. Track cognition, sleep/mood and neurologic symptoms; CBC/CMP are general safety measures.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Systematic human safety data are limited. Reported or plausible effects include headache, dizziness, fatigue, irritability, sleep changes, nausea and injection/nasal-site irritation depending on route.

Contraindications

No validated broad contraindication profile exists. Avoid unsupervised use in pregnancy/breastfeeding, severe psychiatric instability, seizure disorders or major neurologic disease unless the research/clinical protocol specifically addresses it.

Interactions

Formal interaction studies are limited. CNS-active medicines, sedatives, stimulants, antidepressants, anxiolytics and anticonvulsants may alter or obscure effects and should be reviewed clinically.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Pinealon is scientifically interesting for cognition, neuroprotection, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Cognitive

Cognitive

Adamax

Semax-derived nootropic research focused on BDNF signaling, neuroprotection, and cognitive performance.

Read guide

Cognitive

Cerebrolysin

Neurotrophic peptide mixture researched for neuroprotection, neuronal recovery, and cognitive function.

Read guide

Cognitive

PE-22-28

Experimental TREK-1 antagonist peptide research focused on neuroplasticity and mood-related pathways.

Read guide